The Answer to Your Question

Are PARP inhibitors the best choice for me?

The one-size-fits-all approach to treating cancer can leave patients wondering if each treatment will work for them. myChoice HRD is a test to help get the right treatment, to the right patient with ovarian cancer, at the right time.

By testing your tumor tissue, myChoice HRD can help you and your doctor make an informed decision on whether PARP inhibitors are the best choice for you.\textsuperscript{1,2,3}

myChoice HRD identifies more patients likely to benefit from PARP inhibitor therapy than other testing approaches.\textsuperscript{4,5}

What is a PARP inhibitor?

PARP inhibitors are an effective treatment option for patients with ovarian cancer. PARP inhibitors are oral drugs that are used to treat cancer or possibly delay its recurrence.

They have been shown to work the best in patients with \textit{BRCA1/2} mutations or those whose tumors are HRD positive.

Talk to your provider to see if myChoice HRD testing will help inform your cancer treatment.

What is myChoiceHRD?

myChoice HRD tests your tumor to see if it is more likely to respond to PARP inhibitors. It assesses the \textit{BRCA1} and \textit{BRCA2} genes in the tumor along with 3 biomarkers associated with homologous recombination deficiency (HRD). Patients whose tumors have alterations in these genes or biomarkers have been shown to be more likely to benefit from PARP inhibitor therapy.\textsuperscript{1,2,3}

By testing the tumor instead of the blood or saliva, myChoice HRD is able to identify more patients who may benefit from PARP inhibitors.\textsuperscript{4,5}

myChoice HRD Process

1. Tumor tissue is removed through biopsy or surgery
2. Tumor tissue is sent to Myriad for analysis
3. Myriad performs myChoice HRD testing
4. Results are sent to ordering healthcare provider

If you and your doctor decide that testing is right for you, they will typically order myChoice HRD on tumor tissue stored from a prior surgery or schedule a biopsy.

Your results will let you know how much you will benefit from PARP inhibitors. A positive result means you are more likely to benefit from PARP inhibitor therapy and a negative result means you are less likely to benefit from PARP inhibitor therapy.\textsuperscript{1,2,3}
Frequently Asked Questions

How is myChoice HRD ordered?
myChoice HRD can only be ordered by a qualified healthcare professional. Talk with your doctor about myChoice HRD and how it can impact your ovarian cancer treatment.

If I have already had BRCA testing, do I need to be retested?
Based on your previous test results you may or may not need another test. It is important to know that myChoice HRD assesses BRCA1 and BRCA2 genes in the tumor along with 3 biomarkers associated with homologous recombination deficiency (HRD) and can be a helpful tool for those who tested negative for genetic mutations in BRCA1 and BRCA2. myChoice HRD also tests the tumor for BRCA1 and BRCA2 mutations which is capable of identifying more mutations than a blood or saliva test. Talk to your physician about whether you should be tested.

How do I get tested if I had surgery several years ago?
Tumor tissue is typically stored for at least 5 years after surgery and can usually be identified and sent to Myriad for testing. If no tumor tissue is left from your initial ovarian cancer surgery, your doctor may decide to perform a biopsy to get more tissue for myChoice HRD testing.

Can I get tested if I did not and plan not to have any surgery for my ovarian cancer?
myChoice HRD is a tumor test and requires a tumor sample. If you do not plan on having surgery or a biopsy to obtain tumor tissue then you may wish to consider a different type of test to inform PARP inhibitor treatment decisions. For example, Myriad’s BRACAnalysis CDx® test can be performed on a blood sample and used as an aid in identifying ovarian cancer patients who are or may become eligible for treatment with Lynparza™. For more information on BRACAnalysis CDx, please visit BRACNow.com.

Will my health insurance cover myChoice HRD?
At Myriad, we believe every patient should have access to the highest quality testing because we know how useful it is in helping healthcare providers deliver the best medical care. When one of our tests is ordered for you, we will work with your insurance provider to help you get the appropriate coverage allowed by your plan. If you have questions about billing or coverage, please call Myriad at 877-283-6709 for more details.

Where can I learn more about PARP inhibitor therapy?
The current PARP inhibitor therapies approved by the FDA for cancer treatment are Rubraca™ (rucaparib), Lynparza™ (olaparib) and Zejula™ (niraparib). Talk to your provider about getting tested to find out if these treatment options may be right for you.*

* Myriad myChoice HRD has not been approved by the FDA.

Want more information about myChoice HRD?
Talk to your doctor, or visit: myChoiceHRD.com

Sources:

www.myChoiceHRD.com